Phase 1/2Active, not recruiting
PrProfile: A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ION717
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION717 in Patients With Prion Disease
- Sponsor
- Ionis Pharmaceuticals, Inc. (Industry)
- Enrolment
- 85 enrolled
- Conditions
- Prion Disease
- Interventions
- ION717; Placebo
- Ages
- adults, older adults
- Registry
- NCT06153966
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal (IT) delivery of ION717.
Primary outcomes
- Incidence of treatment-emergent adverse events.
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered